214 related articles for article (PubMed ID: 37036661)
1. Renal improvement and remission in a patient with refractory ANCA-associated vasculitis treated with avacopan.
Alvarez L; Kambham N; Su R
J Nephrol; 2023 Nov; 36(8):2365-2370. PubMed ID: 37036661
[TBL] [Abstract][Full Text] [Related]
2. Avacopan as an additional therapeutic intervention to promote renal recovery in severe ANCA-associated vasculitis: A case report.
Atrens AD; Hutton H; O'Sullivan E; Moore J; Madhan K
Nephrology (Carlton); 2024 Feb; 29(2):105-107. PubMed ID: 37985226
[TBL] [Abstract][Full Text] [Related]
3. [Update on treatment of ANCA-associated vasculitis: Granulomatosis with polyangiitis and Microscopic Polyangiitis].
Holle JU; Hellmich B; Moosig F
Z Rheumatol; 2022 May; 81(4):280-285. PubMed ID: 35061059
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of avacopan in patients with ANCA-associated vasculitis receiving rituximab in a randomised trial.
Geetha D; Dua A; Yue H; Springer J; Salvarani C; Jayne D; Merkel P;
Ann Rheum Dis; 2024 Jan; 83(2):223-232. PubMed ID: 37979959
[TBL] [Abstract][Full Text] [Related]
5. Avacopan, a selective C5a receptor antagonist, for anti-neutrophil cytoplasmic antibody-associated vasculitis.
Harigai M; Takada H
Mod Rheumatol; 2022 Apr; 32(3):475-483. PubMed ID: 34984461
[TBL] [Abstract][Full Text] [Related]
6. Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW; Merkel PA; Schall TJ; Bekker P;
N Engl J Med; 2021 Feb; 384(7):599-609. PubMed ID: 33596356
[TBL] [Abstract][Full Text] [Related]
7. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW; Bruchfeld AN; Harper L; Schaier M; Venning MC; Hamilton P; Burst V; Grundmann F; Jadoul M; Szombati I; Tesař V; Segelmark M; Potarca A; Schall TJ; Bekker P;
J Am Soc Nephrol; 2017 Sep; 28(9):2756-2767. PubMed ID: 28400446
[TBL] [Abstract][Full Text] [Related]
8. Management of primary vasculitides with biologic and novel small molecule medications.
Serling-Boyd N; Wallace ZS
Curr Opin Rheumatol; 2021 Jan; 33(1):8-14. PubMed ID: 33164993
[TBL] [Abstract][Full Text] [Related]
9. Updates in ANCA-associated vasculitis.
Ross C; Makhzoum JP; Pagnoux C
Eur J Rheumatol; 2022 Jul; 9(3):153-166. PubMed ID: 35156630
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing and treating ANCA-associated vasculitis: an updated review for clinical practice.
Chevet B; Cornec D; Casal Moura M; Cornec-Le Gall E; Fervenza FC; Warrington KJ; Specks U; Berti A
Rheumatology (Oxford); 2023 May; 62(5):1787-1803. PubMed ID: 36315063
[TBL] [Abstract][Full Text] [Related]
11. The management of anti-neutrophil cytoplasmic antibody-associated vasculitis: what has changed in the last 10 years?
Suresh E
Br J Hosp Med (Lond); 2022 Feb; 83(2):1-10. PubMed ID: 35243884
[TBL] [Abstract][Full Text] [Related]
12. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
13. Avacopan: First Approval.
Lee A
Drugs; 2022 Jan; 82(1):79-85. PubMed ID: 34826105
[TBL] [Abstract][Full Text] [Related]
14. Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT.
Jayne D; Walsh M; Merkel PA; Peh CA; Szpirt W; Puéchal X; Fujimoto S; Hawley C; Khalidi N; Jones R; Flossmann O; Wald R; Girard L; Levin A; Gregorini G; Harper L; Clark W; Pagnoux C; Specks U; Smyth L; Ito-Ihara T; de Zoysa J; Brezina B; Mazzetti A; McAlear CA; Reidlinger D; Mehta S; Ives N; Brettell EA; Jarrett H; Wheatley K; Broadhurst E; Casian A; Pusey CD
Health Technol Assess; 2022 Sep; 26(38):1-60. PubMed ID: 36155131
[TBL] [Abstract][Full Text] [Related]
15. Obinutuzumab as treatment for ANCA-associated vasculitis.
Amudala NA; Boukhlal S; Sheridan B; Langford CA; Geara A; Merkel PA; Cornec D
Rheumatology (Oxford); 2022 Aug; 61(9):3814-3817. PubMed ID: 34958343
[TBL] [Abstract][Full Text] [Related]
16. Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
Alihosseini C; Kopelman H; Zaino M; Feldman SR
Ann Pharmacother; 2023 Dec; 57(12):1449-1454. PubMed ID: 36975183
[TBL] [Abstract][Full Text] [Related]
17. A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain.
Macía M; Díaz-Encarnación M; Solans-Laqué R; Mallol EP; Castells AG; Escribano C; de Arellano AR
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):227-235. PubMed ID: 38126738
[TBL] [Abstract][Full Text] [Related]
18. Treatment of severe renal disease in ANCA positive and negative small vessel vasculitis with rituximab.
Shah S; Hruskova Z; Segelmark M; Morgan MD; Hogan J; Lee SK; Dale J; Harper L; Tesar V; Jayne DR; Geetha D
Am J Nephrol; 2015; 41(4-5):296-301. PubMed ID: 26044574
[TBL] [Abstract][Full Text] [Related]
19. Treatment Approaches to Granulomatosis with Polyangiitis and Microscopic Polyangiitis.
Berti A; Cornec D; Dua AB
Rheum Dis Clin North Am; 2023 Aug; 49(3):545-561. PubMed ID: 37331732
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
